_version_ 1785051274223288320
author Vaxman, I.
Kumar, S. K.
Buadi, F.
Lacy, M. Q.
Dingli, D.
Hayman, S.
Kourelis, T.
Warsame, R.
Hwa, Y.
Fonder, A.
Hobbs, M.
Muchtar, E.
Leung, N.
Kapoor, P.
Go, R.
Lin, Y.
Gonsalves, W.
Siddiqui, M.
Kyle, R. A.
Rajkumar, S. V.
Gertz, M. A.
Dispenzieri, A.
author_facet Vaxman, I.
Kumar, S. K.
Buadi, F.
Lacy, M. Q.
Dingli, D.
Hayman, S.
Kourelis, T.
Warsame, R.
Hwa, Y.
Fonder, A.
Hobbs, M.
Muchtar, E.
Leung, N.
Kapoor, P.
Go, R.
Lin, Y.
Gonsalves, W.
Siddiqui, M.
Kyle, R. A.
Rajkumar, S. V.
Gertz, M. A.
Dispenzieri, A.
author_sort Vaxman, I.
collection PubMed
description
format Online
Article
Text
id pubmed-10229532
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102295322023-06-01 Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience Vaxman, I. Kumar, S. K. Buadi, F. Lacy, M. Q. Dingli, D. Hayman, S. Kourelis, T. Warsame, R. Hwa, Y. Fonder, A. Hobbs, M. Muchtar, E. Leung, N. Kapoor, P. Go, R. Lin, Y. Gonsalves, W. Siddiqui, M. Kyle, R. A. Rajkumar, S. V. Gertz, M. A. Dispenzieri, A. Blood Cancer J Correspondence Nature Publishing Group UK 2023-05-31 /pmc/articles/PMC10229532/ /pubmed/37253713 http://dx.doi.org/10.1038/s41408-023-00859-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Vaxman, I.
Kumar, S. K.
Buadi, F.
Lacy, M. Q.
Dingli, D.
Hayman, S.
Kourelis, T.
Warsame, R.
Hwa, Y.
Fonder, A.
Hobbs, M.
Muchtar, E.
Leung, N.
Kapoor, P.
Go, R.
Lin, Y.
Gonsalves, W.
Siddiqui, M.
Kyle, R. A.
Rajkumar, S. V.
Gertz, M. A.
Dispenzieri, A.
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
title Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
title_full Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
title_fullStr Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
title_full_unstemmed Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
title_short Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
title_sort daratumumab, carfilzomib, and pomalidomide for the treatment of poems syndrome: the mayo clinic experience
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10229532/
https://www.ncbi.nlm.nih.gov/pubmed/37253713
http://dx.doi.org/10.1038/s41408-023-00859-x
work_keys_str_mv AT vaxmani daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT kumarsk daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT buadif daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT lacymq daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT dinglid daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT haymans daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT kourelist daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT warsamer daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT hway daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT fondera daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT hobbsm daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT muchtare daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT leungn daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT kapoorp daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT gor daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT liny daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT gonsalvesw daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT siddiquim daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT kylera daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT rajkumarsv daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT gertzma daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience
AT dispenzieria daratumumabcarfilzomibandpomalidomideforthetreatmentofpoemssyndromethemayoclinicexperience